PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) Director Clay Thorp bought 4,000 shares of the company’s stock in a transaction on Tuesday, December 4th. The stock was purchased at an average cost of $3.13 per share, for a total transaction of $12,520.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NASDAQ PHAS opened at $4.09 on Friday. PhaseBio Pharmaceuticals Inc has a 52 week low of $2.55 and a 52 week high of $6.00.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) last issued its quarterly earnings data on Thursday, November 29th. The company reported ($10.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($10.23). The firm had revenue of $0.41 million during the quarter. As a group, equities analysts anticipate that PhaseBio Pharmaceuticals Inc will post -12.08 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4001090/insider-buying-phasebio-pharmaceuticals-inc-phas-director-acquires-4000-shares-of-stock.html.
About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.